Sagimet Prices $115 Million Offering to Fund Denifanstat and Drug Pipeline

Sagimet Biosciences priced an underwritten offering expected to generate about $115 million in gross proceeds, giving the clinical-stage biotech additional capital for denifanstat and other fatty acid synthase inhibitor programs.

The company is selling 8,750,010 shares of Series A common stock at $10 apiece. Certain investors may instead buy pre-funded warrants covering 2,750,010 shares for $9.9999 per warrant. Those warrants carry an exercise price of $0.0001 per share and can be exercised immediately, which means the purchase price plus exercise price is effectively $10 for each underlying share.

In its pricing announcement, Sagimet said all of the securities are being sold by the company. The offering is expected to close on or about October 1, subject to customary closing conditions, and the $115 million figure is before underwriting discounts, commissions and other offering expenses.

Sagimet is adding capital after a $175 million April financing

The new financing comes only months after Sagimet completed another underwritten equity raise. In April, the company sold 29,166,700 shares at $6 each for $175 million in gross proceeds. By June 30, Sagimet reported $257.6 million in cash, cash equivalents and marketable securities and said that balance was expected to fund current operations through 2028, including through the readout of its planned Phase 3 acne trial for denifanstat.

Adding the two announced 2026 equity financings produces $290 million of gross proceeds before fees and expenses. That arithmetic does not mean Sagimet has $290 million of new cash available today, since the April offering has already been reflected in the company’s reported cash position and the September offering had not yet closed when it was priced. The company also did not provide a new cash-runway estimate in Wednesday’s pricing release, so it would be premature to extend its previously stated 2028 runway by a specific amount.

The financing was led by Commodore Capital, with participation from institutional investors including RA Capital Management, Spruce Street Capital, BVF Partners, Aberdeen Investments, Columbia Threadneedle Investments, Affinity Asset Advisors and Woodline Partners. Leerink Partners, TD Cowen, Guggenheim Securities and Oppenheimer are joint bookrunning managers.

Sagimet also changed another part of its capital-raising setup on September 30. In a prospectus supplement filed with the Securities and Exchange Commission, the company suspended and terminated the continuous offering under an at-the-market sales agreement established in August 2025. Sagimet said it had not sold any shares through that program. The sales agreement itself remains in effect, but the company said it will not make sales under it unless and until a new prospectus supplement is filed.

Denifanstat Phase 3 work is the largest named use of proceeds

Sagimet said it plans to use the net proceeds from the new offering, together with its existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial of denifanstat in acne and pre-launch activities for the drug. The company also named development of TVB-3567 through Phase 2 topline results and advancement of a topical FASN inhibitor program through an Investigational New Drug application as intended uses. Remaining funds may go toward other clinical development, working capital and operating expenses.

Denifanstat is an oral, once-daily inhibitor of fatty acid synthase, or FASN, that Sagimet is developing for moderate to severe acne in the United States. The planned AURORA Phase 3 trial is designed to enroll about 800 U.S. patients aged 12 and older, including roughly 450 adolescents. Sagimet said in August that all clinical trial sites had been identified, a contract research organization had been retained, and patient screening was expected to begin in October with the first enrollment shortly afterward.

The timing of the offering also follows new denifanstat data from Sagimet’s license partner Ascletis BioScience in China. On September 30, Sagimet reported 52-week results from an open-label extension of a Phase 3 acne study. The company said 240 patients entered the extension and that the pooled treatment-success rate at the end of the trial was 56.7%, with mean reductions of 71.8% in total lesion count and 76.9% in inflammatory lesion count compared with the original study baseline. Sagimet described the drug as generally well tolerated, with no adverse-event-related permanent discontinuations in the extension.

Those China results do not replace the U.S. AURORA study. Sagimet has said the U.S. trial will be randomized, double blind and placebo controlled, with three co-primary endpoints assessed after 12 weeks. A subset of patients is expected to continue into a 40-week open-label extension for longer-term safety evaluation. Sagimet has said it anticipates submitting a new drug application after completing the 12-week phase, but any approval would still depend on the clinical program and subsequent regulatory review.

Pre-funded warrants alter the security mix, not the $115 million headline

The pre-funded warrants are an alternative to common shares for investors that choose them, rather than an extra block of securities priced on top of the 8.75 million common shares. Sagimet set the warrant purchase price at $9.9999 and the later exercise price at $0.0001, so the two amounts add to the same $10 economic price as the common stock in the offering.

If all 2,750,010 pre-funded warrants are ultimately exercised, they would result in the issuance of the same number of Series A common shares. Combined with the 8,750,010 shares being sold directly, the financing therefore covers 11,500,020 shares or underlying shares.

For Sagimet, the more important operating question is how the additional capital is deployed across a pipeline that is moving toward more expensive later-stage development. Denifanstat is entering a large U.S. Phase 3 trial, Sagimet plans to move TVB-3567 beyond first-in-human work subject to regulatory feedback, and the topical FASN program is still earlier in development. Each step requires clinical, regulatory and manufacturing spending before any product can generate commercial revenue.

The offering is scheduled to close around October 1 if the closing conditions are met. After that, the next concrete milestones are the expected start of AURORA patient screening in October and Sagimet’s planned advancement of TVB-3567 toward Phase 2. The company has not yet disclosed a revised cash-runway estimate incorporating the new financing.